My hon. Friend is making a very powerful speech. May I congratulate her on securing this debate, and say how proud I am to be a co-signatory? The phenomenon of there being drugs in the pipeline that would make a vital difference to patients, but which are being held up by conflict between NICE and pharmaceutical companies over pricing or value for money, applies not only to breast cancer but to other cancers, too. My constituent David Innes is one of 20,000 sufferers of chronic lymphocytic leukaemia. He was diagnosed in 2009, when he was 39. He was in Parliament earlier this week, making the same argument, and saying that both parties need to end the logjam and come up with a deal to ensure the availability of these drugs. They need to put patients first. Life is too short not to do so.
Breast Cancer Drugs
Proceeding contribution from
Rupa Huq
(Labour)
in the House of Commons on Thursday, 26 January 2017.
It occurred during Backbench debate on Breast Cancer Drugs.
Type
Proceeding contribution
Reference
620 c508 
Session
2016-17
Chamber / Committee
House of Commons chamber
Librarians' tools
Timestamp
2024-08-13 12:55:28 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012637000354
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012637000354
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012637000354